Regenxbio (RGNX) Cost of Revenue (2014 - 2024)

Regenxbio's Cost of Revenue history runs 11 years deep, the most recent figure standing at $6.3 million for Q4 2024.

• In Q4 2024, Cost of Revenue fell 43.78% year-over-year to $6.3 million; the TTM figure through Dec 2024 stood at $33.6 million (down 9.8% YoY), while the FY2024 annual figure was $33.6 million, down 9.8% from the prior year.
• Cost of Revenue was $6.3 million for Q4 2024 at Regenxbio, down from $12.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $23.1 million in Q4 2021 to a low of $3.4 million in Q1 2020.
• Historically, Cost of Revenue has averaged $10.6 million across 5 years, with a median of $10.9 million in 2023.
• The sharpest annual moves came in 2020 and 2023: Cost of Revenue soared 11655.17% in 2020, then slumped 73.84% in 2023.
• A 5-year view of Cost of Revenue shows it stood at $10.3 million in 2020, then jumped by 124.8% to $23.1 million in 2021, then slumped by 44.56% to $12.8 million in 2022, then dropped by 12.09% to $11.2 million in 2023, then sank by 43.78% to $6.3 million in 2024.
• The last three Cost of Revenue figures came in at $6.3 million (Q4 2024), $12.4 million (Q3 2024), and $10.6 million (Q2 2024), per Business Quant data.